

Conference

EARLY INTERVENTION IN PSYCHOSIS

Current
knowledge
and future
directions

May 27 – 28, 2013

Douglas Hall, Douglas Mental Health
University Institute

Conference also available live via webcast

This conference is supported by a knowledge dissemination grant
from the CIHR Institute of Neurosciences, Mental Health and Addiction.
Additional support has been provided through an unrestricted
educational grant from Bristol-Myers Squibb.

Douglas
INSTITUT MENTAL HEALTH
UNIVERSITAIRE EN UNIVERSITY
SANTÉ MENTALE INSTITUTE

 **McGill**

PEPP
MONTREAL


IRSC CIHR
Instituts de recherche Canadian Institutes of
en santé du Canada Health Research

Conference

EARLY
INTERVENTION
IN PSYCHOSIS

Current
knowledge
and future
directions

REGISTRATION FORM

Last Name:

First Name:

Occupation:

I WANT TO ATTEND THE CONFERENCE:

- Physicians and other professionals: **\$350**
- Residents and students*: **\$100**
- Non-profit organization employees: **\$100**

I WANT TO HAVE ACCESS TO THE CONFERENCE VIA WEBCAST:

- Physicians and other professionals: **\$350**
- Residents and students*: **\$100**
- Non-profit organization employees: **\$100**

Employer:

Address:

Postal Code:

Phone:

Fax:

Email (obligatory):

SIMULTANEOUS TRANSLATION SERVICES**:

- Yes
- No

CONFERENCE INFORMATION

INFORMATION RELATED TO REGISTRATION

Please make your cheque payable to the Research Centre, Douglas Hospital. To pay by credit card, please go online to peppmontreal.ca.

To be valid, all registration must be paid.

No reimbursements after May 17, 2013.

REGISTRATION AND INFORMATION

Jessy Ranger
Communication Advisor
Douglas Institute
Dobell Pavilion, Room B-1136
6875, LaSalle Boulevard
Montreal (Quebec) H4H 1R3
Tel.: 514-761-6131, ext. 2616
jessy.ranger@douglas.mcgill.ca

POSTER SUBMISSION

Please send poster abstracts to elizabeth.lee@douglas.mcgill.ca by April 5, 2013. Consult peppmontreal.ca for submission details.

-
- * A valid ID card is required
 - ** Simultaneous translation is not available via webcast.

OBJECTIVES

The following objectives relate to psychosis in youth:

To learn about a new system of mental health care for youth

To update our knowledge about the clinical relevance of cognition and neuroimaging

To improve our understanding of psychological, social, and cross-cultural aspects (including stigma)

To acquire knowledge about complexities of substance abuse and risks to physical health and well-being associated with psychosis

A certificate of attendance will be issued by email to all participants.


This event will be accredited by Continuing Medical Education, McGill University, Canada.

INTRODUCTION

This conference is the largest and the most comprehensive conference on early intervention and prevention for psychosis held in Canada since the IEPA in 2004. The conference brings together renowned researchers and clinicians, from different parts of the world, to disseminate the most up to date knowledge on neurobiological, social, psychological, and cultural aspects of the early phases of psychotic disorders, as well as on challenging problems related to substance abuse and physical health.

A two-hour open forum, with participation from service providers and users, policy makers and clinician-scientists, will explore application of this knowledge to tackle challenges posed in service delivery for young people suffering from psychosis. There will be a poster session where individuals from different early intervention services will present their work.

This conference is designed to disseminate practical knowledge to clinicians, researchers, students, administrators, and representatives from the government and to help translate research into practice and policy, so that young people suffering from psychosis receive the best possible services and increase their chances of recovery.



Ashok Malla, MD, FRCPC

Director, Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute; Professor, Department of Psychiatry, McGill University (Canada); Canada Research Chair in Early Psychosis



PROGRAM

Day 1
May 27

8:30 a.m.

Opening remarks

- Lynne McVey, RN, MSc
- André Delorme, MD, FRCPC
- Mimi Israël, MD, FRCPC

OVERVIEW: SYNTHESIS OF KNOWLEDGE IN THE FIELD OF EARLY INTERVENTION FOR PSYCHOSIS

Chair: Ashok Malla, MD, FRCPC

9:00 a.m.

Plenary lecture

Early intervention for psychosis: a new architecture and culture of care

Patrick McGorry, MD, PhD

10:00 a.m.

Overview of accumulated knowledge and achievements at PEPP-Montréal

Ashok Malla, MD, FRCPC

10:30 a.m.

Break

NEUROBIOLOGY AND ITS IMPLICATIONS FOR CLINICAL AND FUNCTIONAL OUTCOME

Chair: Martin Lepage, PhD

10:50 a.m.

Plenary lecture

Third-generation neuroimaging in early schizophrenia: translating research evidence into clinical utility

Stefan Borgwardt, MD

11:30 a.m.

Early identification of neurobiological markers of remission in first-episode psychosis

Michael Bodnar, PhD

11:50 a.m.

Neurocognition and neuroimaging of persistent negative symptoms in first-episode psychosis

Cindy Hovington, PhD candidate

12:10 p.m.

Neurocognitive deficits and functional outcome in early psychosis: what do we know and what can we do about it?

Srividya Iyer, PhD

12:30 p.m.

Lunch

SOCIAL AND PSYCHOLOGICAL ASPECTS OF EARLY INTERVENTION AND RECOVERY

Chair: Alain Lesage, PhD

1:30 p.m.

Plenary lecture

Social anxiety disorder in early phase psychosis: the role of shame sensitivity and diagnosis concealment

Max Birchwood, PhD

2:15 p.m.

Plenary lecture

Stigma and early intervention for psychosis: can we shrink the elephant in the room?

Ross M.G. Norman, PhD

3:00 p.m.

Break

3:20 p.m.

The personal meaning of recovery among individuals treated for a first episode of psychosis

Deborah Windell, MSc

3:40 p.m.

Group cognitive behavior therapy for social anxiety in psychosis: does it work?

Tina Montreuil, PhD

4:00 p.m.

Psychological and biological correlates of stress in ultra-high risk and first-episode psychosis patients

Marita Pruessner, PhD

4:20 p.m.

Discussion

5:00 p.m.

Peer-reviewed poster session

Day 1

Day 2

PROGRAM

Day 2
May 28

CULTURE AND PSYCHOSIS

Chair: Laurence Kirmayer, MD

9:00 a.m.

Plenary lecture

Is early intervention a priority in developing countries? Issues and challenges

Thara Rangaswamy, MD, PhD

9:50 a.m.

The clinical presentation of first-episode psychosis across different migrant and ethnic minority groups in Montreal, Quebec

Elsje Van der Ven, PhD candidate

10:10 a.m.

The role of family factors in outcome differences in first-episode psychosis in Chennai, India, and Montreal, Canada

Ramesh Kumar, MD

10:30 a.m.

Ethnicity and pathways to care in early intervention for psychosis

Kelly Anderson, PhD

11:00 a.m.

Break

COMORBIDITIES AND PSYCHOSIS

Chair: Ridha Joober, MD, PhD

11:10 a.m.

Plenary lecture

Responding to the challenge of treatment of individuals with co-occurring substance abuse and psychotic disorders: a focus on youth and young adults

Lisa Dixon, MD, MPH

12:00 p.m.

Exploring the complex interplay between cannabis use, medication adherence, and symptom intensity in first-episode psychosis

Kia Faridi, MD

12:20 p.m.

Lunch

1:30 p.m.

Cannabis and psychosis: is there an aspect of psychotic illness that promotes cannabis use?

Clifford Cassidy, PhD candidate

1:50 p.m.

Medical comorbidities in the early phase of psychosis: what can we do about it?

Aldanie Rho, MPH

OPEN FORUM AND DISCUSSION PANEL (2 HOURS)

Chairs: Patrick McGorry, MD, PhD, and
Amparo Garcia, MA, IMHL

2:10 p.m.

Discussion of key issues such as models of care, translation of knowledge into service, how to influence policy, length of treatment, disengagement from treatment, shift away from diagnosis, cultural issues related to FEP and early intervention, possible collaborations and research priorities.

FORUM MEMBERS

Service user; family member of a service user; service providers from Quebec and other parts of Canada; community service providers; mental health policy and academic personnel.

Lectures will be mostly given in English with simultaneous translation in French on demand.

Day 1

Day 2

OUR SPEAKERS

PLENARY SPEAKERS

Max Birchwood, PhD

Clinical Director, Youthspace Mental Health Programme; Birmingham and Solihull Mental Health Trust; Professor, School of Psychology, University of Birmingham (United Kingdom)

Stefan Borgwardt, MD

Department of Psychiatry and Medical Image Analysis Centre, University of Basel (Switzerland); Institute of Psychiatry, Department of Psychosis Studies, King's College, London (United Kingdom)

Lisa Dixon, MD, MPH

Director, Centre for Practice Innovations, New York State Psychiatric Institute; Professor, Department of Psychiatry, Columbia University (USA)

Ashok Malla, MD, FRCPC

Director, Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute; Professor and Canada Research Chair in Early Psychosis, Department of Psychiatry, McGill University (Canada)

Patrick McGorry, MD, PhD

Executive Director, Orygen Youth Health Research Centre; Professor, Centre for Youth Mental Health, University of Melbourne; Director of Clinical Services, Orygen Youth Health (Australia)

Ross M.G. Norman, PhD

Professor, Departments of Psychiatry and Epidemiology & Biostatistics, University of Western Ontario; Director of Research, Department of Psychiatry, University of Western Ontario (Canada)

Thara Rangaswamy, MD, PhD

Director, Schizophrenia Research Foundation, Chennai (India)

SPECIAL GUESTS AND SESSION CHAIRS

André Delorme, MD, FRCPC

National Director of Mental Health, Ministère de la Santé et des Services sociaux, Québec (Canada)

Amparo Garcia, MA, IMHL

Director of the Clinical Activities, Knowledge Transfer and Teaching Directorate, Douglas Institute (Canada)

Mimi Israël, MD, FRCPC

Psychiatrist-in-Chief, Douglas Institute; Chair of the Department of Psychiatry, McGill University; Associate Professor, Department of Psychiatry, McGill University (Canada)

Ridha Joobar, MD, PhD

Assistant Director, Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute; Associate Professor, Department of Psychiatry, McGill University (Canada)

Laurence Kirmayer, MD

James McGill Professor and Director, Division of Social and Transcultural Psychiatry, Department of Psychiatry, McGill University (Canada)

Martin Lepage, PhD

Associate Professor, Department of Psychiatry, McGill University; Researcher, Douglas Institute (Canada)

Alain Lesage, PhD

Associate Director, Fernand-Seguin Research Centre, Hôpital Louis-H. Lafontaine; Professor, Department of Psychiatry, Université de Montréal (Canada)

Lynne McVey, RN, MSc

Executive Director, Douglas Institute (Canada)

OTHER INVITED SPEAKERS

Kelly Anderson, PhD

Post-doctoral fellow, Centre for Addictions and Mental Health, Toronto (Canada)

Michael Bodnar, PhD

Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute (Canada)

Clifford Cassidy, PhD candidate

Department of Psychiatry, McGill University; Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute (Canada)

Kia Faridi, MD

Psychiatrist, Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute; Assistant Professor, Department of Psychiatry, McGill University (Canada)

Cindy Hovington, PhD candidate

McGill University; Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute (Canada)

Srividya Iyer, PhD

Program Coordinator, Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute; Assistant Professor, Department of Psychiatry, McGill University (Canada)

Ramesh Kumar, MD

Psychiatrist, Researcher, Schizophrenia Research Foundation, Chennai (India)

Tina Montreuil, PhD

Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute (Canada)

Marita Pruessner, PhD

Program Coordinator, Clinic for the Assessment of Youth at Risk (CAYR), sub-service of Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute; Assistant Professor, Department of Psychiatry, McGill University (Canada)

Aldanie Rho, MPH

Project Coordinator, Prevention and Early Intervention Program for Psychoses (PEPP-Montréal), Douglas Institute (Canada)

Elsje Van der Ven, PhD candidate

Rivierduinen Institute for Mental Health Care, Oegstgeest; Department of Psychiatry and Psychology, Maastricht University, Maastricht (Netherlands)

Deborah Windell, MSc

Prevention and Early Intervention Program for Psychoses, London, Ontario (Canada)



ABOUT PEPP-MONTRÉAL

The Prevention and Early Intervention Program for Psychoses (PEPP-Montréal) is an internationally renowned, integrated clinical research program dedicated to providing assessment and treatment services for young adults experiencing the early stages of psychosis. Its team of clinicians and research staff work with individuals in the early stages of psychosis and their families to help them resume functioning and achieve their personal recovery goals. This program operates under the aegis of the Douglas Mental Health University Institute (Douglas Institute), which is affiliated with McGill University in Montreal (Canada). This international conference has been organized to mark the 10th anniversary of PEPP-Montréal in 2013.

In 2003, Dr. Ashok Malla established PEPP-Montréal as a two-year treatment program for individuals with first-episode psychosis. In 1996, Dr. Malla had established a similar program, PEPP-London, at the University of Western Ontario in London, Ontario (Canada). In its beginnings, PEPP-Montréal was a small one-room clinic located temporarily in the Frank B. Common Pavilion at the Douglas Institute and had a total of 17 staff members. Over the past decade, it has grown into a large program that now occupies the Wilson Pavilion, with a total of 41 core staff members and several other affiliates and collaborators. In 2005, the Clinic for

Assessment of Youth at Risk (CAYR) was established as a sub-clinic of PEPP-Montréal. CAYR is an integrated clinical research service for youth at high risk for developing psychosis. By January 2013, 506 young people with first-episode psychosis had received services from PEPP-Montréal and 122 young people had received services from the CAYR program.

PEPP-Montréal has made significant contributions (over 150 publications and 200 conference presentations) to research-based knowledge in early psychosis. These contributions have helped advance understanding in the field and have had a positive impact on outcomes for youth with psychosis. PEPP-Montréal is also an active training and teaching site for students from various disciplines and visitors from various clinics, from within and outside Canada. PEPP-Montréal hopes to continue its clinical, research and teaching mandate with the overarching goal of improving the quality of life of young people with psychosis and their families in Canada and around the world.

